MilliporeSigma’s ZooMAb® Antibodies Earns First-Ever ACT Label from My Green Lab

The first-ever antibody to achieve ACT label designation, ZooMAb® antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category.

14 Apr 2022 | Burlington, Massachusetts, United States of America
  • ZooMAb® antibodies became the first-ever antibody to be recognized for low-environmental impact by My Green Lab
  • ZooMAb® antibodies ranked most impactful on the environment in the chemicals and reagents category by My Green Lab
  • ACT label enables scientists to choose more sustainable products

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its ZooMAb® recombinant antibodies platform earned Accountability, Consistency and Transparency (ACT) label from My Green Lab, a non-profit organization dedicated to creating a culture of sustainability in science.

The first-ever antibody to achieve ACT label designation, ZooMAb® antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category­.

“Helping our customers and suppliers to reduce their impact on the environment is a key part of our sustainability strategy,” said Jeffrey Whitford, Head of Sustainability and Social Business Innovation, MilliporeSigma. “By showing how products rate in different categories, such as manufacturing; energy and water use; packaging; and end-of-life, the ACT label gives scientists another data point to help increase their sustainability. We are proud to be part of this program and are thrilled to achieve one of the top ranking EIF scores for our ZooMAb® antibodies.”

Unlike traditional monoclonal antibodies, or mAbs, made from identical immune cells from an animal-sourced parent cell, ZooMAb® antibodies use recombinant technology. This offers an endless and consistent supply, while reducing the use of animals in research.

ZooMAb® antibodies can be shipped at room temperature and then stored between 2°C and 8°C, while traditional mAbs must be shipped and stored between 2°C and 8°C, eliminating the need for specially insulated, ice-cooled containers that contribute to high packaging material consumption and transport emissions. Shipping ZooMAb® antibodies, which weigh 2.5 g or about as heavy as a penny, at room temperature, allows for more opportunities to eventually ship the product in much smaller packaging, preventing the emission of around 175 metric tons of CO2 per year by 2025.

In addition to innovation and packaging, the following factors contributed to the low EIF score:

  • The manufacturing facility where the ZooMAb® antibodies are produced has implemented energy, water and waste reduction measures; produced renewable energy from a wind farm; and has an environmental management system program that is ISO 14001 certified.
  • ZooMAb® antibodies do not contain any Red List chemicals, CMRs, PBTs or GreenScreen Benchmark-1 chemicals.

Downloads

For more information please contact Rachel Bloom-Baglin

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated sales of € 19.7 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Related News

  1. Press Releases

    MilliporeSigma Announces the Expansion of Hands-On Science Education Program ...

    The Curiosity Cube®—a retrofitted shipping container that features hands-on science experiments designed to spark student interest in STEM careers—will engage young minds at schools and public spaces.

    2022/05/18